Actavis Pharma Partnering Guide 2008 Provides A Firm Basis for Initial Due Diligence into Actavis as A Prospective Partner Company.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/research/8fc139/actavis_pharma Pharma may be an abbreviation for:
In the late 1990s, Actavis employed fewer than one hundred people and operated solely in the Icelandic market. Pharma Partnering Guide 2008" company profile to their offering. The Actavis Partnering Guide 2008 provides an in-depth in-depth adj. Detailed; thorough: an in-depth study. in-depth Adjective detailed or thorough: an in-depth analysis insight into the partnering interests and activities of one of the world's leading biopharma companies. This report provides all the information you require to better understand Actavis and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate INITIATE. A right which is incomplete. By the birth of a child, the husband becomes tenant by the curtesy initiate, but his estate is not consummate until the death of the wife. 2 Bouv. Inst. n. 1725. discussions. Using this report, dealmakers will effectively and efficiently determine the suitability of Actavis as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners. The report provides a firm basis for initial due diligence Research; analysis; your homework. This term has caught on in all industries, because it sounds so "wired." Who would want to do analysis or research when they can do due diligence. See wired. into Actavis as a prospective partner company. Key benefits: Actavis Partnering Guide 2008 report provides the user with the following key benefits; - Detailed company profile of the company - In-depth marketed and pipeline product activity for the company - Partnering interests and therapy focus revealed - Partnering activity since 2000 - number of deals per year - Partnering activity for 2005-2008 - Activity by deal type - Activity by phase of development - Activity by therapeutic area - List of recent partner companies - Comprehensive access to actual contracts entered into by the company and its partners (1) - Insight into the terms included in a partnering agreement - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies (1) Subject to being published via regulatory requirements Regulatory requirements are part of the process of drug discovery and drug development. Regulatory requirements describe what is necessary for a new drug to be approved for marketing in any particular country. of the Securities Exchange Commission. Report Scope: Actavis Partnering Guide 2008 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's approach to partnering. Actavis Partnering Guide 2008 includes: Detailed company profile including: -Full contact details -Business developer contact details including name, title, email and telephone (where available) -Marketed indications -Pipeline indications -Partnering interests and indications -Partnering activity since 2000 -Current partner companies since 2005 Partnering activity since 2005 by: -Deal type -Stage of development -Therapy area -Numerous charts showing the dealmaking activity of the company since 2005 -The tools to enable effective and efficient preparation for partnering negotiation with the company -Listing of contract documents between the company and its partners -The leading M&A and partnering deals by value 2005-8 -Most active M&A and partnering dealmakers 2005-8 The Actavis Partnering Guide 2008 report also provides comprehensive access to available contract documents for the company. Analyzing actual company agreements allows assessment of the following: - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality Restrictions on the accessibility and dissemination of information. Confidentiality is one of the six fundamental components of information security (see Parkerian Hexad). and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated ter·mi·nate v. ter·mi·nat·ed, ter·mi·nat·ing, ter·mi·nates v.tr. 1. To bring to an end or halt: ? - What happens when there is a change of ownership? - What sublicensing and subscontracting provisions have been agreed? - Which boilerplate A phrase or body of text used verbatim in different documents such as a signature at the end of a letter. Boilerplate is widely used in the legal profession as many paragraphs are used over and over in agreements with little modification or no modification. clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Executive Summary: The initial chapters of this report provide an orientation orientation, in architecture, the disposition of the parts of a building with reference to the points of the compass. From remote antiquity the traditional belief in the efficacy of religious ceremonials performed at dawn toward the rising sun has influenced the of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2007 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2007 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005-7 according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. reported deal size. Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face. Chapter 7 provides a series of matrices that summarize sum·ma·rize intr. & tr.v. sum·ma·rized, sum·ma·riz·ing, sum·ma·riz·es To make a summary or make a summary of. sum the company's activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area. The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function. The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type - therefore co-promotion Co-promotion is a marketing practice where a company in addition to its own, uses another company's sales force to promote the same brand or range of brands. The term is frequently confused with Co-marketing. See also Marketing co-operation deals are listed separately to licensing, M&A and supply deals, and so on. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Bigpharma - The Top 50 Chapter 3 - Most active bigpharma dealmakers 3.1 Bigpharma M&A activity 3.2 Bigpharma partnering Chapter 4 - Top bigpharma deals - 2000-7 4.1 Bigpharma M&A 4.2 Bigpharma partnering Chapter 5 - Submitting Opportunities to Bigpharma such as Actavis 5.1 How to submit an opportunity 5.2 Opportunity submission Submission Elliott, Anne reluctantly gives up her fiancé on her family’s advice. [Br. Lit.: Jane Austen Persuasion in Magill I, 734] template (1) A pre-designed document or data file formatted for common purposes such as a fax, invoice or business letter. If the document contains an automated process, such as a word processing macro or spreadsheet formula, then the programming is already written and embedded in the 5.3 Sending emails 5.4 Face to face at partnering events 5.5 Online submission forms Chapter 6 - Forthcoming bigpharma partnering events 6.1 Forthcoming events Chapter 7 - Actavis - therapy locator 7.1 How to use the therapy matrix tables 7.2 Therapeutic area definitions 7.3 Actavis - Therapeutic target matrix - marketed and pipeline compounds 7.5 Actavis - Therapeutic target matrix - expressed partnering interests 7.6 Actavis - Therapeutic target matrix - recent deals - 2005-2007 Chapter 8 - Bigpharma Company Profiles 8.1 How to use company profiles 8.2 Field definitions 8.3 Actavis company profile Company contact details Subsidiary companies Primary therapy areas Business development contacts Company description Marketed therapeutic indications Pipeline (phase I-III) therapeutic indications Partnering interests Partnering interests - therapeutic indications Partnering frequency per annum Per annum Yearly. - 2000-2008 Current partner companies (2005-8) Recent deals 2005-2008 By deal type By stage of development By therapy area Contract documents available online - link direct to each document List of Figures Figure 1: Bigpharma - top 50 by pharma revenues 2007 Figure 2: Leading Bigpharma M&A companies, 2005-7 Figure 3: Leading Bigpharma partnering companies, 2005-7 Figure 4: Leading M&A deals involving bigpharma by value, 2005-7 Figure 5: Leading partnering deals by value, 2005-7 Figure 6: Typical partnering opportunity submission template Figure 7: Partnering events 2008-9 Figure 8: Therapeutic area definitions Figure 9: Therapeutic target matrix - marketed and pipeline compounds Figure 10: Therapeutic target matrix - expressed partnering interests Figure 11: Therapeutic target matrix - recent deals 2005-7 Figure 12: Company profile template and definitions used in report Figure 13: Actavis - Dealmaking frequency 2000-2007 Figure 14: Actavis - recent deals (2005-2008) by deal type Figure 15: Actavis - recent deals (2005 - 2008) by stage of development Figure 16: Actavis - recent deals (2005 - 2008) by therapy area Figure 17: Recent Actavis partnering deals (2003-2008) where contract document available Figure 18: Online partnering resources For more information visit http://www.researchandmarkets.com/research/8fc139/actavis_pharma_par |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion